[HTML][HTML] The role of alternative splicing in cancer: From oncogenesis to drug resistance
R Sciarrillo, A Wojtuszkiewicz, YG Assaraf… - Drug Resistance …, 2020 - Elsevier
Alternative splicing is a tightly regulated process whereby non-coding sequences of pre-
mRNA are removed and protein-coding segments are assembled in diverse combinations …
mRNA are removed and protein-coding segments are assembled in diverse combinations …
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
A Sveen, S Kilpinen, A Ruusulehto, RA Lothe… - Oncogene, 2016 - nature.com
Alternative splicing is a widespread process contributing to structural transcript variation and
proteome diversity. In cancer, the splicing process is commonly disrupted, resulting in both …
proteome diversity. In cancer, the splicing process is commonly disrupted, resulting in both …
Molecular map of chronic lymphocytic leukemia and its impact on outcome
Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …
Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types
M Seiler, S Peng, AA Agrawal, J Palacino, T Teng… - Cell reports, 2018 - cell.com
Hotspot mutations in splicing factor genes have been recently reported at high frequency in
hematological malignancies, suggesting the importance of RNA splicing in cancer. We …
hematological malignancies, suggesting the importance of RNA splicing in cancer. We …
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is a frequent disease in which the genetic alterations
determining the clinicobiological behaviour are not fully understood. Here we describe a …
determining the clinicobiological behaviour are not fully understood. Here we describe a …
Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer
Tumor-associated epitopes presented on MHC-I that can activate the immune system
against cancer cells are typically identified from annotated protein-coding regions of the …
against cancer cells are typically identified from annotated protein-coding regions of the …
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia
Charting differences between tumors and normal tissue is a mainstay of cancer research.
However, clonal tumor expansion from complex normal tissue architectures potentially …
However, clonal tumor expansion from complex normal tissue architectures potentially …
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations
A Pellagatti, RN Armstrong, V Steeples… - Blood, The Journal …, 2018 - ashpublications.org
Abstract SF3B1, SRSF2, and U2AF1 are the most frequently mutated splicing factor genes in
the myelodysplastic syndromes (MDS). We have performed a comprehensive and …
the myelodysplastic syndromes (MDS). We have performed a comprehensive and …
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction
W Zhang, Y Yu, F Hertwig, J Thierry-Mieg, W Zhang… - Genome biology, 2015 - Springer
Background Gene expression profiling is being widely applied in cancer research to identify
biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for …
biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for …